Phenotypic detection of carbapenemase production in carbapenem-resistant isolates with the rapid carbapenemase detection method (rCDM)

Çalık, Şeyma; Kansak, Nilgün; Aksaray, Sebahat

doi:10.1016/j.mimet.2022.106536

Cited by 5 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than one carbapenemase gene was detected among 79/80 Klebsiella isolates and in all E. coli isolates. These findings were similarly stated by other researchers [18,20,30,31,[34][35][36]. Hereby, the high prevalence of more than one carbapenemase gene in Enterobacterales isolates may illustrate the hastily propagating resistance.…”

Section: Discussionsupporting

confidence: 84%

Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope

Taha

Kader²,

Shawky³

et al. 2023

Ann Clin Microbiol Antimicrob

View full text Add to dashboard Cite

Background Carbapenemase-producing Enterobacterales (CPE) show rapid global dissemination and pose a significant therapeutic challenge. This study aimed to characterize carbapenemase-producing Klebsiella spp. and Escherichia coli (E. coli) phenotypically and genotypically and evaluate the effect of ceftazidime/ avibactam plus aztreonam combination. Methods A total of 219 Klebsiella species and 390 E. coli strains were isolated from clinical samples, in which 80 Klebsiella spp. and 20 E coli isolates were resistant to tested carbapenems (imipenem, ertapenem, meropenem) by disk diffusion/broth dilution method and Vitek-2 compact system. MASTDISCS Combi Carba plus discs and real time PCR were used to determine type of carbapenemase phenotypically and genotypically, respectively. Interestingly, the synergistic effect between ceftazidime-avibactam (E-test) and aztreonam (disc) was tested against the CPE isolates. Results Out of the carbapenem-resistant isolates, 76.25% Klebsiella spp. isolates were extensively drug-resistant (XDR) while 18.75% were pan drug-resistant (PDR), and 5% were multidrug-resistant (MDR). Regarding E. coli, 5% were PDR, 20% were MDR and 75% were XDR. More than one carbapenemase gene was detected in 99% of the isolates. In comparison between MAST-Carba plus discs and PCR results, sensitivity and specificity were (85.42–97.92%) in Klebsiella spp., and (69.64–100%) in E. coli, respectively. Moreover, a strong association was detected between both test results among Klebsiella spp. (p < 0.001) and E. coli (p = 0.012) isolates. Finally, ceftazidime-avibactam and aztreonam combination showed a synergistic effect in 98.8% of Klebsiella spp. and 95% of E coli. All 16 PDR isolates showed synergy. Conclusion This synergistic effect spots the light on new therapeutics for XDR and PDR CPE.

show abstract

Section: Discussionsupporting

confidence: 84%

Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope

Taha

Kader²,

Shawky³

et al. 2023

Ann Clin Microbiol Antimicrob

View full text Add to dashboard Cite

show abstract

“…Our country, Türkiye, is the country that detected the first OXA-48 positive strain [11]. OXA-48 was the most common gene in strains resistant to carbapenems, and although it is still the predominant carbapenemase enzyme in our country, NDM and KPC are becoming increasingly detected in CRKP isolates [4,12]. Newer antibiotics such as ceftazidime/avibactam, imipenem/relabactam, and meropenem/vaborbactam are effective against some carbapenemase-positive strains, but none are effective against metallo-beta-lactam-containing strains, nor are meropenem/vaborbactam or imipenem/relabactam-carrying OXA-48 strains [13].…”

Section: Discussionmentioning

confidence: 95%

“…The presence of major carbapenem resistance genes (bla KPC , bla NDM , bla VIM , bla IMP , bla OXA-51 , bla OXA23/58 , bla OXA-48 ) and carbapenemase enzymes have been determined in our laboratory in a previous study [4]. These CRKP strains were included; seven isolates from each of bla KPC , bla OXA-48 , and bla OXA-48þ bla NDM and seven strains free of specified genes.…”

Section: Materials and Methods Collection Of Carbapenem Resistant Str...mentioning

confidence: 99%

Investigation of in vitro efficacy of meropenem/polymyxin B and meropenem/fosfomycin combinations against carbapenem resistant Klebsiella pneumoniae strains

Adaleti

Nakipoğlu

Çalık

et al. 2023

AMicr

View full text Add to dashboard Cite

The incidence of infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) is increasing worldwide, and very limited number of effective antibiotics are available for therapy. In our study, the in vitro efficacy of meropenem/polymyxin B and meropenem/fosfomycin combinations against CRKP strains was investigated. The efficiency of meropenem/polymyxin B and meropenem/fosfomycin combinations was tested by checkerboard microdilution and checkerboard agar dilution methods, respectively, against 21 CRKP strains containing major carbapenem resistant genes (7 blaKPC, 7 blaOXA-48 gene, and 7 blaOXA-48+ blaNDM), and seven additional CRKP strains without carbapenemase genes.Among the 28 CRKP strains, the meropenem/polymyxin B combination was synergistic in ten (35.7%), partially synergistic in 12 (42.8%), and indifferent in six (21.4%) isolates. The meropenem/fosfomycin combination was found to be synergistic in three isolates (10.7%), partially synergistic in 20 (71.4%), and indifferent in five (17.8%). In 21 strains containing carbapenem resistance genes, meropenem/polymyxin B and meropenem/fosfomycin combinations exhibited synergistic/partial synergistic effects in 15 (71.4%) and 16 (76.2%) strains, respectively, compared to 100% synergistic/partial synergistic efficiency in both combinations in seven strains free of carbapenemase genes. No antagonistic effect was detected in either combination.Regardless of presence or absence of carbapenem resistance genes, meropenem/polymyxin B and meropenem/fosfomycin combinations both demonstrated high synergistic and partial synergistic activity against 78.4% and 82.1% of CRKP strains, respectively. Also, they have no antagonistic effects and can be used successfully to prevent therapeutic failure with monotherapy, according to our in vitro studies.

show abstract

“…Clinicians should know that different TOL/TAZ susceptibility testing methods used in different studies might have a potential impact on activity results. In addition to conventional and time-consuming culture methods, the use of rapid multiplex PCR assay allowing early detection of carbapenemase genes (such as KPC, OXA-48, NDM, VIM, and IMP) can exhibit positive impact on administering appropriate antibiotics earlier and avoiding unnecessary prescriptions [ 30 , 31 ]. For instance, TOL/TAZ is suitable for P. aeruginosa that is resistant to carbapenem but lacks a carbapenemase gene, while other molecules such as ceftazidime-avibactam may be of interest to target isolates expressing either KPC or OXA-48 carbapenemase [ 32 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

Ceftolozane/tazobactam: Literature review of its activity on Taiwanese isolates before its launch in Taiwan (2012–2021)

Chao,

2024

Heliyon

View full text Add to dashboard Cite

Phenotypic detection of carbapenemase production in carbapenem-resistant isolates with the rapid carbapenemase detection method (rCDM)

Cited by 5 publications

References 11 publications

Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope

Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope

Investigation of in vitro efficacy of meropenem/polymyxin B and meropenem/fosfomycin combinations against carbapenem resistant Klebsiella pneumoniae strains

Ceftolozane/tazobactam: Literature review of its activity on Taiwanese isolates before its launch in Taiwan (2012–2021)

Contact Info

Product

Resources

About